![]() | You can help expand this article with text translated from the corresponding article in Hebrew. (November 2021) Click [show] for important translation instructions.
|
![]() The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center. | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Other names | Brilife |
Routes of administration | Intramuscular |
ATC code |
|
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search